Clinical Trials
31 trialsNCT04557059 2026-06-05
PRIMORDIUM
Janssen Pharmaceutica N.V., Belgium
Phase 3 Active not recruiting
NCT00945009 2026-06-03
Combination Chemotherapy and Surgery in Treating Young Patients With Wilms Tumor
Children's Oncology Group
Phase 3 Completed
NCT06770582 2026-06-03
Testing the Addition of the Immunotherapy Drug, Pembrolizumab, to Radiation Therapy Compared to the Usual Chemotherapy Treatment During Radiation Therapy for Bladder Cancer, PARRC Trial
National Cancer Institute (NCI)
Phase 2 Recruiting
NCT03775265 2026-05-29
Chemoradiotherapy With or Without Atezolizumab in Treating Patients With Localized Muscle Invasive Bladder Cancer
National Cancer Institute (NCI)
Phase 3 Active not recruiting
NCT02177292 2026-05-26
SIB
Medical College of Wisconsin
Phase NA Active not recruiting
NCT07607431 2026-05-26
AWARE
Rigshospitalet, Denmark
Active not recruiting
NCT02799706 2026-05-22
PEGASUS
European Organisation for Research and Treatment of Cancer - EORTC
Phase 3 Active not recruiting
NCT04216290 2026-05-22
A Study of Chemotherapy and Radiation Therapy Compared to Chemotherapy and Radiation Therapy Plus MEDI4736 (Durvalumab) Immunotherapy for Bladder Cancer Which Has Spread to the Lymph Nodes, INSPIRE Trial
National Cancer Institute (NCI)
Phase 2 Active not recruiting
NCT03274687 2026-05-20
Hypofractionated Radiation Therapy or Conventional Radiation Therapy After Surgery in Treating Patients With Prostate Cancer
NRG Oncology
Phase 3 Completed
NCT03987386 2026-05-20
Conventional or Hypofractionated Radiation Therapy in Treating Patients With Prostate Cancer
M.D. Anderson Cancer Center
Phase 3 Active not recruiting
NCT04879940 2026-05-20
Phase II Study to Evaluate the Safety and Efficacy of Prostatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Active not recruiting
NCT07477626 2026-05-19
RADVAN
Sun Yat-sen University
Phase 3 Active not recruiting
NCT04947254 2026-05-15
Androgen Ablation Therapy With or Without Niraparib After Radiation Therapy for the Treatment of High-Risk Localized or Locally Advanced Prostate Cancer
M.D. Anderson Cancer Center
Phase 2 Recruiting
NCT06586255 2026-05-14
Adjuvant Concurrent Immunotherapy and Radiotherapy for the Treatment of Bladder Cancer
Abramson Cancer Center at Penn Medicine
Phase 1 Recruiting
NCT07578519 2026-05-11
Radiation Treatment of the Prostate That is Specially Adjusted for Each Person
AHS Cancer Control Alberta
Phase 2 Not yet recruiting
NCT04134260 2026-05-07
Testing the Addition of the Drug Apalutamide to the Usual Hormone Therapy and Radiation Therapy After Surgery for Prostate Cancer, INNOVATE Trial
NRG Oncology
Phase 3 Recruiting
NCT03217747 2026-05-05
Avelumab, Utomilumab, Anti-OX40 Antibody PF-04518600, and Radiation Therapy in Treating Patients With Advanced Malignancies
M.D. Anderson Cancer Center
Phase 1/2 Active not recruiting
NCT04322318 2026-05-05
A Study of Combination Chemotherapy for Patients With Newly Diagnosed DAWT and Relapsed FHWT
Children's Oncology Group
Phase 2 Recruiting
NCT04513717 2026-05-04
Two Studies for Patients With High Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a High Gene Risk Score, The PREDICT-RT Trial
NRG Oncology
Phase 3 Active not recruiting
NCT05050084 2026-05-04
Two Studies for Patients With Unfavorable Intermediate Risk Prostate Cancer Testing Less Intense Treatment for Patients With a Low Gene Risk Score and Testing a More Intense Treatment for Patients With a Higher Gene Risk Score, The Guidance Trial
NRG Oncology
Phase 3 Active not recruiting
NCT07043608 2026-05-01
ZAMBONI
University of California, San Francisco
Phase 2 Not yet recruiting
NCT04902040 2026-04-30
Plinabulin in Combination With Radiation/Immunotherapy in Patients With Select Advanced Cancers After Progression on PD-1 or PD-L1 Targeted Antibodies
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT04984343 2026-04-23
FORT
Weill Medical College of Cornell University
Phase 2 Terminated
NCT06378866 2026-04-20
DIVINE
Mayo Clinic
Phase 2 Recruiting
NCT07237269 2026-04-15
Abi/Pred + ADT vs ADT in PSMA-Positive, Conventionally Node-Negative Prostate Cancer
University of Nebraska
Phase 2 Recruiting
NCT03543189 2026-04-01
Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy
H. Lee Moffitt Cancer Center and Research Institute
Phase 1/2 Active not recruiting
NCT06244004 2026-03-30
FDG-PET-Guided Metastasis Directed Radiation Therapy for the Treatment of Metastatic Hormone Sensitive Prostate Cancer, The PRTY Trial
Northwestern University
Phase 2 Recruiting
NCT05656794 2026-03-23
CONSORT-PC
University Health Network, Toronto
Phase 2 Recruiting
NCT06409910 2026-03-23
AMPORA
University Health Network, Toronto
Phase 2 Recruiting
NCT06282588 2026-03-19
THUNDER
Cancer Research Antwerp
Phase 2/3 Recruiting
NCT07245745 2026-03-16
Prospective Clinical Study Comparing PROMS After Adaptive or Conventional Radiotherapy in Prostate Cancer
Cliniques universitaires Saint-Luc- Université Catholique de Louvain
Phase NA Recruiting